Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

Site for A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.05% Administered QD in Subjects with Atopic Dermatitis

Atopic Dermatitis: Double Blind, 4 weeks study. Topical Cream applied daily. Males/Females 2-5 years with mild to moderate atopic dermatitis. At the week 4 visit subjects may be eligible to enroll in a 12-month, open label extension study. The goal of the study is assess the safety and effectiveness of ARQ-151 0.05% cream.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT04844562
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 2-5 years of age
Exclusion Criteria:
certain medications/treatments are not allowed; study coordinator will discuss further
Subjects currently undergoing allergy testing (food allergy testing or skin prick testing), patch testing, food challenges, or allergy desensitization, or plan to do so during the study
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA